Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

Company Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $3.95 to $4.39
• 50-Day Range: $2.97 to $4.54
• 52-Week Range: $2.86 to $13.70
• Volume: 2.82 million shs
• Average Volume: 995,600 shs
• Market Capitalization: $234.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.33
• Consensus Rating: Hold

Fulcrum Therapeutics Stock Analysis - MarketRank™

Fulcrum Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 724th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Fulcrum Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 3 buy ratings, 6 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Fulcrum Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($0.16) to ($1.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fulcrum Therapeutics is -14.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fulcrum Therapeutics is -14.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fulcrum Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.49% of the outstanding shares of Fulcrum Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Fulcrum Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fulcrum Therapeutics has recently decreased by 2.14%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fulcrum Therapeutics does not currently pay a dividend.

Dividend Growth

Fulcrum Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.49% of the outstanding shares of Fulcrum Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Fulcrum Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fulcrum Therapeutics has recently decreased by 2.14%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.62

News Sentiment

Fulcrum Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Fulcrum Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

1 people have added Fulcrum Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fulcrum Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Fulcrum Therapeutics is held by insiders.

Percentage Held by Institutions

89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FULC Stock Analysis - Frequently Asked Questions

How have FULC shares performed this year?

Fulcrum Therapeutics' stock was trading at $6.75 at the start of the year. Since then, FULC shares have decreased by 35.6% and is now trading at $4.35.
View the best growth stocks for 2024 here.

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.07. The business had revenue of $4.94 million for the quarter, compared to analyst estimates of $2.94 million.

When did Fulcrum Therapeutics IPO?

Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

Who are Fulcrum Therapeutics' major shareholders?

Top institutional investors of Fulcrum Therapeutics include RA Capital Management L.P. (16.39%), FMR LLC (2.76%), State Street Corp (2.69%) and Geode Capital Management LLC (2.12%). Insiders that own company stock include Ra Capital Management, LP, Robert J Gould and Greg Tourangeau.
View institutional ownership trends.

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FULC
• CUSIP: N/A
• CIK: 1680581
• Web: www.fulcrumtx.com
• Phone: (617) 651-8851
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.33
• High Stock Price Target: $23.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +114.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-97,330,000.00
• Net Margins: N/A
• Pretax Margin: -22.15%
• Return on Equity: -7.31%
• Return on Assets: -6.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.44
• Quick Ratio: 18.44

Sales & Book Value

• Annual Sales: $80.87 million
• Price / Sales: 2.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.80 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 53,939,000
• Free Float: 51,728,000
• Market Cap: $234.63 million
• Optionable: Optionable
• Beta: 2.14